Study guide

9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage

Key Takeaways Explain This Topic AI

Gestational hypertension is new hypertension (BP ≥ 140/90 mmHg) presenting after 20 weeks gestation without proteinuria; Pre-eclampsia requires new hypertension after 20 weeks PLUS significant proteinuria (uPCR ≥ 30 mg/mmol or ACR ≥ 8 mg/mmol) or maternal end-organ dysfunction.

High-risk women (prior pre-eclampsia, CKD, chronic hypertension, diabetes, autoimmune disease) must receive prophylactic aspirin 75–150 mg daily from 12 weeks until delivery; oral labetalol is first-line for BP control (target 135/85 mmHg), substituting modified-release nifedipine if asthma is present.

Severe pre-eclampsia and eclampsia are treated with intravenous magnesium sulphate (4 g loading dose over 10–15 min, then 1 g/h for 24h); toxicity is detected by loss of deep tendon reflexes, bradypnoea (<12/min), and oliguria, and is reversed with 10% IV calcium gluconate.

Antepartum haemorrhage mandates distinguishing placenta praevia (painless, bright red bleeding, soft relaxed uterus, high fetal lie; digital vaginal examination is strictly contraindicated prior to scan) from placental abruption (painful, dark/concealed bleeding, rigid 'board-like' tender uterus, maternal shock out of proportion, fetal distress).

Primary postpartum haemorrhage (blood loss of 500 mL or more within 24 hours of any birth; major above 1,000 mL) is driven by the 4 Ts (Tone #1, Tissue, Trauma, Thrombin); uterotonic medical management employs IV oxytocin, ergometrine (contraindicated in hypertension), carboprost (contraindicated in asthma), misoprostol, and IV tranexamic acid.

Last updated: October 2026

Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage

Obstetric emergencies during the second half of pregnancy and the peripartum period are major contributors to maternal and perinatal morbidity. Accurate risk stratification, prompt diagnosis of hypertensive disorders, safe evaluation of antepartum bleeding, and rapid resuscitation during postpartum haemorrhage are vital competencies in UK clinical practice.

Hypertensive Disorders of Pregnancy

Blood pressure normally falls during the first and second trimesters, reaching a nadir at 20–24 weeks, before returning to pre-pregnancy levels by term. New hypertension developing after 20 weeks gestation is classified into distinct clinicopathological entities:

Gestational Hypertension: New-onset systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg arising after 20 weeks of gestation in the absence of significant proteinuria or end-organ dysfunction . Blood pressure characteristically normalises within 6 weeks postpartum.

Pre-Eclampsia: New-onset hypertension (BP ≥ 140/90 mmHg) occurring after 20 weeks gestation accompanied by one or more of the following newly developed features:

Significant Proteinuria: Urine protein:creatinine ratio ( uPCR) ≥ 30 mg/mmol , urine albumin:creatinine ratio ( uACR) ≥ 8 mg/mmol , or 24-hour urine collection ≥ 0.3 g protein (or dipstick ≥ 2+).

Maternal Organ Dysfunction:

Renal: Serum creatinine > 90 µmol/L (or doubling of baseline).

Hepatic: Elevated transaminases (ALT or AST > 70 IU/L, or > twice upper limit of normal) or severe persistent right upper quadrant / epigastric pain.

Haematological: Thrombocytopenia (platelets < 100 × 10⁹/L), DIC, or microangiopathic haemolysis.

Neurological: Severe intractable headache, persistent visual scotomata, photopsia, hyperreflexia with sustained clonus (≥ 3 beats), or eclamptic convulsions.

Respiratory: Acute pulmonary oedema.

Uteroplacental Dysfunction: Severe fetal growth restriction (FGR), oligohydramnios, or abnormal umbilical artery Doppler waveforms.

Risk Stratification & Aspirin Prophylaxis (NICE NG133)

Early prophylactic administration of aspirin 75–150 mg daily from 12 weeks of gestation until birth reduces the incidence of preterm pre-eclampsia in vulnerable women:

  • High-Risk Factors (Offer Aspirin if ≥ 1 Present) Moderate-Risk Factors (Offer Aspirin if ≥ 2 Present)
  • Hypertensive disease in a previous pregnancy • First pregnancy (primigravida)
  • Chronic kidney disease (CKD) • Maternal age ≥ 40 years
  • Autoimmune disease (SLE or Antiphospholipid Syndrome) • Pregnancy interval > 10 years
  • Pre-existing chronic hypertension • Body mass index (BMI) ≥ 35 kg/m² at booking
  • Diabetes mellitus (Type 1 or Type 2) • Family history of pre-eclampsia (mother or sister)
  • Multiple pregnancy (twins, triplets)
  • Pharmacological BP Control

Antihypertensive pharmacotherapy is initiated when blood pressure reaches ≥ 140/90 mmHg , aiming for a target blood pressure of 135/85 mmHg :

First-line: Oral Labetalol (combined alpha- and beta-adrenergic blocker). Titrated up to 200–400 mg three times daily.

Second-line (or in Asthmatic Patients): Nifedipine modified-release (MR, dihydropyridine calcium channel blocker). Labetalol is contraindicated in asthma due to bronchospasm risk.

Third-line: Methyldopa (centrally acting alpha-2 agonist). Note: Methyldopa should be discontinued within 48 hours post-delivery due to high risks of postnatal depression.

Contraindicated Antihypertensives: ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and thiazide diuretics are strictly contraindicated in pregnancy due to risks of fetal renal dysgenesis, oligohydramnios, skull hypoplasia, and intrauterine death.

Severe Pre-Eclampsia & Eclampsia Management

Severe pre-eclampsia is characterized by blood pressure ≥ 160/110 mmHg or pre-eclampsia accompanied by maternal symptoms of impending eclampsia (severe headache, visual disturbance, clonus, epigastric pain):

Acute Blood Pressure Lowering: Intravenous labetalol infusion or intravenous hydralazine infusion, accompanied by oral nifedipine MR.

Eclampsia Prophylaxis & Seizure Control: Intravenous Magnesium Sulphate ( M g S O 4 MgSO_4 M g S O 4 ​ ) is the anticonvulsant of choice:

Loading dose: 4 g IV over 10–15 minutes .

Maintenance infusion: 1 g/hour IV for 24 hours following delivery or the last seizure.

Monitoring for Magnesium Toxicity: Magnesium is cleared almost exclusively by the kidneys. Hourly clinical surveillance must check:

Deep tendon reflexes: Loss of the patellar (knee-jerk) reflex is the earliest sign of toxicity.

Respiratory rate: Must remain ≥ 12 breaths/minute (respiratory depression indicates advanced toxicity).

Urine output: Must exceed 20 mL/hour . If oliguria develops, magnesium rapidly accumulates.

Magnesium Antidote: If toxicity occurs, immediately stop the infusion and administer 10 mL of 10% Calcium Gluconate intravenously over 10 minutes .

HELLP Syndrome

HELLP syndrome is a severe thrombotic microangiopathy complicating 10–20% of severe pre-eclampsia cases:

H (Haemolysis): Microangiopathic haemolytic anaemia with schistocytes/burr cells on blood film, elevated lactate dehydrogenase (LDH > 600 IU/L), and unconjugated hyperbilirubinaemia.

EL (Elevated Liver enzymes): ALT or AST > 70 IU/L; capsular hepatic distension causes epigastric pain and risks subcapsular haematoma rupture.

LP (Low Platelets): Consumptive thrombocytopenia with platelets < 100 × 10⁹/L.

Definitive Treatment: Prompt maternal stabilisation followed by urgent delivery regardless of gestational age.

Antepartum Haemorrhage (APH)

Antepartum haemorrhage is defined as genital bleeding occurring from 24 completed weeks of gestation until delivery of the infant. The two major obstetric causes are placenta praevia and placental abruption.

Clinical Parameter Placenta Praevia Placental Abruption

Underlying Pathology Placenta implanted partially or wholly in the lower uterine segment over or near the internal os Premature detachment of a normally sited placenta from the uterine decidua prior to birth

Nature of Bleeding Painless , recurrent, typically bright red vaginal haemorrhage Painful , continuous, typically dark red bleeding (may be concealed behind placenta in 20%)

Abdominal Palpation Abdomen is soft, relaxed, and non-tender ; uterine fundus matches dates Uterus is tense, rigid, woody, and intensely tender ("board-like abdomen")

Fetal Presentation & Lie Often abnormal lie (transverse, oblique) or high, unengaged presenting part Normal lie; fetal parts difficult to palpate due to severe myometrial hypertonus

Fetal Heart / CTG Usually normal and reassuring unless massive maternal hypovolaemia Frequently abnormal: severe decelerations, fetal bradycardia, or absent heart tones

Maternal Shock Proportional to visible external vaginal blood loss Out of proportion to visible bleeding (due to extensive concealed retroplacental clot)

Coagulopathy (DIC) Rare Common (massive release of tissue thromboplastin into maternal circulation)

Caution

Strict Contraindication in APH: NEVER perform a digital vaginal examination in any woman presenting with antepartum haemorrhage until placenta praevia has been definitively excluded by ultrasound. Digital palpation can tear a low-lying placenta, precipitating catastrophic, fatal haemorrhage within minutes.

Postpartum Haemorrhage (PPH)

Primary postpartum haemorrhage (RCOG Green-top Guideline 52) is blood loss of 500 mL or more from the genital tract within 24 hours of birth , after either vaginal or caesarean birth. Minor PPH is 500–1,000 mL; major PPH is more than 1,000 mL (moderate 1,001–2,000 mL, severe more than 2,000 mL) or any blood loss with clinical shock. Secondary PPH is abnormal bleeding from 24 hours to 12 weeks after birth (often endometritis or retained tissue).

The 4 Ts of PPH Aetiology

Tone (~70–80% of cases): Uterine atony. The uterus is soft, boggy, and relaxed above the umbilicus. Risk factors include prolonged labour, multiparity, multiple pregnancy, polyhydramnios, and chorioamnionitis.

Tissue (~10%): Retained products of conception (cotyledons, succenturiate lobe, placenta accreta) or intra-cavitary blood clots preventing mechanical myometrial retraction.

Trauma (~20%): Lacerations of the perineum, vagina, or cervix, pelvic haematomas, uterine rupture, or acute uterine inversion.

Thrombin (~1%): Pre-existing coagulopathies (von Willebrand disease, haemophilia) or acquired coagulopathies (DIC secondary to abruption, sepsis, or amniotic fluid embolism).

Emergency Resuscitation & Medical Escalation Ladder

When primary PPH is diagnosed, the multidisciplinary obstetric emergency team must be summoned immediately:

Initial Resuscitation: ABCDE approach, 15 L/min high-flow oxygen via non-rebreather mask, two large-bore (14G) IV cannulae , urgent bloods (FBC, coagulation screen, fibrinogen, crossmatch 4–6 units), warmed crystalloids, and insertion of a Foley catheter to decompress the bladder.

Mechanical Compression: Continuous bimanual uterine compression (one gloved hand in the anterior vaginal fornix pressing the anterior uterine wall, the other hand compressing the fundus abdominally) combined with firm uterine fundal rubbing ("rubbing up a contraction").

Pharmacological Uterotonics:

Oxytocin: First-line. Administer 5 units slow IV bolus , followed by an oxytocin infusion ( 40 units in 500 mL normal saline at 125 mL/hour ).

Ergometrine: 500 mcg slow IV or IM. Induces sustained tetanic uterine contractions. CONTRAINDICATED in women with hypertension or pre-eclampsia due to severe acute vasospasm and hypertensive crisis.

Carboprost (15-methyl PGF2-alpha): 250 mcg deep IM repeated every 15 minutes (maximum 8 doses = 2 mg). CONTRAINDICATED in patients with active asthma due to severe bronchoconstriction.

Misoprostol: 800–1000 mcg per rectum or sublingually (synthetic PGE1 analogue).

Tranexamic Acid (TXA): Administer 1 g IV over 10 minutes within 3 hours of delivery (reduces maternal mortality from bleeding without increasing thrombotic complications).

Tamponade & Surgical Interventions: If uterotonics fail, escalate rapidly to intrauterine balloon tamponade ( Bakri balloon ), surgical haemostatic brace suturing ( B-Lynch suture ), bilateral uterine artery ligation, interventional radiological arterial embolisation, or emergency peripartum hysterectomy as a lifesaving final measure.

Loading diagram... Emergency Escalation Algorithm for Primary Postpartum Haemorrhage